Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Summary

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.

Timeline

Start

2021-01-07

Primary completion

2027-04-30

Completion

2027-04-30

Publications

• Ganti AKP, Loo BW Jr, Badiyan S, Bassetti M, Bestvina C, Chiang A, Choudhury N, D'Avella CA, Daly M, Dowlati A, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Khalil M, Lee R, Malhotra J, Merritt RE, Mohindra N, Molina JR, Moran C, Mulvey C, Osmundson EC, Patel S, Patil T, Pokharel S, Puri S, Qin A, Sands J, Shields M, Tailor TD, Waqar SN, Cassara CJ, Ramakrishnan S. NCCN Guidelines(R) Insights: Small Cell Lung Cancer, Version 2.2026. J Natl Compr Canc Netw. 2026 Jan;24(1):e260002. doi: 10.6004/jnccn.2026.0002.

Drugs

Indications